2. Signaling Pathways
  3. Apoptosis
  4. IAP
  5. IAP Isoform

IAP

 

IAP Related Products (33):

Cat. No. Product Name Effect Purity
  • HY-16591
    Birinapant
    		Antagonist 99.70%
    Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
  • HY-15518
    LCL161
    		Inhibitor 99.91%
    LCL161 is a IAP inhibitor which inhibits XIAP in HEK293 cell and cIAP1 in MDA-MB-231 cell with IC50s of 35 and 0.4 nM, respectively.
  • HY-16701
    BV6
    		Antagonist 99.90%
    BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family.
  • HY-12486
    FL118
    		Inhibitor 99.40%
    FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin (HY-16560) analogue, is a potent and orally active survivin inhibitor. FL118 binds to oncoprotein DDX5 (p68) to dephosphorylates and degrades DDX5. FL118 can be used for the research of cancer.
  • HY-109565
    Tolinapant
    		Antagonist 99.81%
    Tolinapant (ASTX660) is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
  • HY-13638
    GDC-0152
    		Inhibitor 99.67%
    GDC-0152 is a potent IAPs inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of ML-IAP with Ki values of 28 nM, 17 nM, 43 nM and 14 nM, respectively.
  • HY-15835
    CUDC-427
    		Inhibitor 99.01%
    CUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.
  • HY-125593
    Dasminapant
    		Antagonist 99.36%
    Dasminapant (APG-1387), a bivalent SMAC mimetic and an IAP antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma.
  • HY-100892
    MX69
    		Inhibitor 99.88%
    MX69 is an inhibitor of MDM2/XIAP, used for cancer treatment.
  • HY-149924
    CST626
    		Degrader
    CST626 (Compound 9) is a pan-IAP degrader PROTAC. CST626 degrades XIAP, cIAP1 and cIAP2 with DC50s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively.
  • HY-12842
    UC-112
    		Inhibitor 98.92%
    UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.
  • HY-N6064
    Polygalacin D
    		Inhibitor 99.95%
    Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis
  • HY-124181
    SM-1295
    		Antagonist 98.71%
    SM-1295 is an inhibitor of apoptosis protein (IAP) antagonist, with Kd values of 3077 nM, 3.2 nM and 9.5 nM for XIAP-BIR3, c-IAP1-BIR3 and c-IAP2-BIR3, respectively.
  • HY-138059
    SM-433
    		Inhibitor 99.01%
    SM-433, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2).
  • HY-113534
    MV1
    		Antagonist 98.47%
    MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand.
  • HY-50685
    A 410099.1
    		Inhibitor 99.30%
    A 410099.1 is a BIRC inhibitor, with EC50 values for BIRC2, BIRC3, BIRC4, BIRC7, and BIRC8 are 4.6, 9.2, 15.6, 19.9, and 93.9 nM, respectively.
  • HY-115865
    XIAP degrader-1
    		Inhibitor 99.31%
    XIAP degrader-1, a primary amine tethered small molecule, promotes the degradation of X-linked inhibitor of apoptosis protein (XIAP).
  • HY-78144
    4-Methylsalicylic acid
    		Inhibitor 99.85%
    4-Methylsalicylic acid is a salicylic acid. 4-Methylsalicylic acid derivative is a selective tissue-nonspecific alkaline phosphatase (TNAP) and intestinal alkaline phosphatase (IAP) inhibitor.
  • HY-138059A
    SM-433 hydrochloride
    		Inhibitor 98.57%
    SM-433 hydrochlorid, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 hydrochlorid exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2).
  • HY-155019
    Anticancer agent 128
    		Inhibitor
    Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 128 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 24.9 nM, 19.3 nM, and 10.3 nM, respectively.